CA2923421A1 - Methods of determining response to therapy - Google Patents

Methods of determining response to therapy Download PDF

Info

Publication number
CA2923421A1
CA2923421A1 CA2923421A CA2923421A CA2923421A1 CA 2923421 A1 CA2923421 A1 CA 2923421A1 CA 2923421 A CA2923421 A CA 2923421A CA 2923421 A CA2923421 A CA 2923421A CA 2923421 A1 CA2923421 A1 CA 2923421A1
Authority
CA
Canada
Prior art keywords
mice
metadoxine
erk
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2923421A
Other languages
English (en)
French (fr)
Inventor
Jonathan Rubin
Yaron DANIELY
Johanna SCHUMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Ltd
Original Assignee
Alcobra Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Alcobra Ltd filed Critical Alcobra Ltd
Publication of CA2923421A1 publication Critical patent/CA2923421A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2923421A 2013-09-09 2014-09-09 Methods of determining response to therapy Abandoned CA2923421A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 2013-09-26
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09
PCT/US2014/054816 WO2015035402A1 (en) 2013-09-09 2014-09-09 Methods of determining response to therapy

Publications (1)

Publication Number Publication Date
CA2923421A1 true CA2923421A1 (en) 2015-03-12

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2923421A Abandoned CA2923421A1 (en) 2013-09-09 2014-09-09 Methods of determining response to therapy
CA2922901A Abandoned CA2922901A1 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2922901A Abandoned CA2922901A1 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Country Status (12)

Country Link
EP (2) EP3044589A1 (ja)
JP (2) JP2016530536A (ja)
KR (2) KR20160086818A (ja)
CN (2) CN105517546A (ja)
AU (2) AU2014316779A1 (ja)
CA (2) CA2923421A1 (ja)
EA (2) EA201690557A1 (ja)
IL (2) IL244343A0 (ja)
MX (2) MX2016003006A (ja)
SG (2) SG11201601605YA (ja)
TW (2) TW201606304A (ja)
WO (2) WO2015035402A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109021022B (zh) * 2013-07-31 2021-04-16 Udc 爱尔兰有限责任公司 发光的二氮杂苯并咪唑碳烯金属配合物
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
EP3773538A1 (en) * 2018-04-13 2021-02-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
KR20210035802A (ko) * 2018-06-07 2021-04-01 오비드 테라퓨틱스 인크. 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용
US20230024384A1 (en) * 2020-01-08 2023-01-26 Neuroventi Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders
WO2021158059A1 (ko) * 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
CN102481291B (zh) * 2009-06-25 2015-10-21 阿尔考布拉有限公司 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法

Also Published As

Publication number Publication date
KR20160086818A (ko) 2016-07-20
SG11201601605YA (en) 2016-04-28
MX2016003006A (es) 2016-06-10
TW201605443A (zh) 2016-02-16
EP3044589A1 (en) 2016-07-20
MX2016003002A (es) 2016-09-08
KR20160078956A (ko) 2016-07-05
EA201690559A1 (ru) 2016-08-31
JP2016530291A (ja) 2016-09-29
CN105917225A (zh) 2016-08-31
EA201690557A1 (ru) 2016-07-29
AU2014316779A1 (en) 2016-03-17
SG11201601830PA (en) 2016-04-28
AU2014315026A1 (en) 2016-03-24
IL244343A0 (en) 2016-04-21
WO2015035402A1 (en) 2015-03-12
EP3043792A2 (en) 2016-07-20
TW201606304A (zh) 2016-02-16
CA2922901A1 (en) 2015-03-12
CN105517546A (zh) 2016-04-20
WO2015033224A3 (en) 2015-07-02
JP2016530536A (ja) 2016-09-29
WO2015033224A2 (en) 2015-03-12
IL244453A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CA2923421A1 (en) Methods of determining response to therapy
Taubes et al. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease
Stessman et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases
Swindell et al. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia
Fromer et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia
Jang et al. Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder
Haberman et al. Prominent hippocampal CA3 gene expression profile in neurocognitive aging
Wells et al. The anatomical distribution of genetic associations
Tan et al. Mouse models as a tool for discovering new neurological diseases
US20140323581A1 (en) Transcriptome wiring analysis in parkinson's disease and uses thereof
Tandon et al. Machine learning selection of most predictive brain proteins suggests role of sugar metabolism in Alzheimer’s disease
US9851355B2 (en) Methods of determining response to therapy
Li et al. Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data
Mathys et al. Single-cell multiregion dissection of Alzheimer’s disease
EP4067504A1 (en) Use of synaptotagmin-7 in the diagnosis and treatment of bipolar disorder
Wang et al. Molecular networks and key regulators of the dysregulated neuronal system in Alzheimer’s disease
Bhuvaneshwar et al. Translational bioinformatics and data science for biomarker discovery in mental health: an analytical review
Cruchaga et al. Multi-tissue proteomics identifies molecular signatures for sporadic and genetically defined Alzheimer disease cases
Runge et al. Disruption of the transcription factor NEUROD2 causes an autism syndrome via cell-autonomous defects in cortical projection neurons
Du et al. Developing a novel immune infiltration-associated mitophagy prediction model for amyotrophic lateral sclerosis using bioinformatics strategies
Sannah Hippocampal Differential Gene Expression Converges Across Animal Models of Mood Disorder: Results From An Interactive Meta-Analysis Pipeline Encompassing Five Animal Models
WO2022203533A1 (ru) Способ оценки предрасположенности к различным формам сахарного диабета 2го типа
Wang et al. Trajectory of plasma lipidomes associated with the risk of late-onset Alzheimer’s disease pathogenesis: a longitudinal study in the ADNI cohort
Restrepo Cross-species Exploration of Inhibitory Control: The Role of Netrin-1/DCC System in Corticolimbic Development
Green et al. Cellular communities reveal trajectories of brain ageing and Alzheimer’s disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180911